INTRODUCTION

Primary central nervous system lymphoma (PCNSL)
is increasing and is now one of the most important neoplasms in neurooncology. This disease has most often been treated with radiation therapy [1, 2] . Although the tumor also responds to chemotherapy and favorable results have been reported for patients treated with combination of radiation and chemotherapy, the role of chemotherapy still remains controversial, due to the lack of randomized studies comparing radiation plus chemotherapy with radiation alone [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The favorable results reported for patients receiving the combination therapy may be due to the selection of patients with favorable outcome [15] . Thus, the standard treatment for PCNSL remains to be determined in future studies.
Corticosteroids are known to possess prominent oncolytic effects in PCNSL in addition to their effects to ameliorate cerebral edema. Most PCNSL diminish in size following systemic administration of corticosteroids, and even long-term control of PCNSL has been reported following steroid treatment alone [16] [17] [18] . Corticosteroids do not produce severe adverse effects which anticancer agents can produce, but long-term use of steroids can produce other complications which are quite different from those of anticancer agents. Because of the difference in toxicity, it may be useful to effectively combine steroid with radiotherapy and/or chemotherapy. To prevent recurrence of PCNSL by maximally utilizing the lympholytic effect of corticosteroids and avoiding their systemic adverse effects, we have used intraarterial topical administration of corticosteroids fol- The first patient with recurrent disease received focal radiation with 20 Gy. All the other patients received whole-brain radiotherapy to a dose of 30-50 Gy followed by 0-20 Gy of focal boost. The daily dose of 2 Gy was given 5 times a week. The total radiation dose was 40-60 Gy. Whole-brain radiation was given by parallel opposed fields, and focal booster doses were given by parallel opposed or lateral single field. Three of the patients received 1,2 or 5 courses of high-dose intravenous methotrexate (3g/m2) accompanied with leucovorin rescue (15 or 21 mg given 6 or 12 times following each methotrexate administration) before radiotherapy. The other 2 patients received intrathecal cytarabine (20 mg X 5) injection during radiation therapy. Three patients received systemic corticosteroids for 2-14 days after operation or during radiotherapy.
One to 15 days after completing radiation therapy, corticosteroids were given intraarterially by Seldinger's method. Prednisolone was used in 7 patients, while dexamethazone was used in the other patient. Depending on the tumor location and spread, varying doses of the steroids were injected through internal carotid arteries and in 5 of the patients also through the left vertebral artery. In the first patient, 30 mg of prednisolone was given first, and then 60 mg was given again 1 month later. The total dose of prednisolone was 60 mg in the second and third patients. The fourth patient received 12 mg of dexamethazone which is equivalent to 60 mg prednisolone. The use of dexamethazone was to investigate feasibility of the drug which can be given in smaller volumes of solution. The total dose of prednisolone was increased to 75 mg in the fifth patient, and then to 100 mg in the remaining patients.
Response to treatment was evaluated by means of magnetic resonance imaging (MRI) during and immediately after radiotherapy, and after corticosteroid treatment. Also, MRI was repeated at 3-4 month intervals thereafter.
RESULTS
All patients completed the planned treatment.
After corticosteroid administration, all patients were in good conditions. So far, no acute or late compli- 
DISCUSSION
It is well known that PCNSL responds to corticosteroids. This lympholytic effect of steroids is mediated by cytoplasmic steroid receptors which are translocated to the nucleus and signal apoptosis [18] . This particular response to steroids can be quite helpful in establishing clinical diagnosis of PCNSL [18, 19] , but obscures histological diagnosis when given before biopsy [20] . In addition to the direct effect on lymphoma cells, the "trafficking effect;' that is to prevent malignant lymphoma cells from entering CNS, is also postulated [21] . If this postulation is true, steroids may play a role in preventing CNS relapse of lymphoma.
Since the effect of steroids is high, it seems reasonable to use corticosteroids in the treatment of PCNSL. Some PCNSL's disappear following systemic administration of moderate doses of steroids, and long-term control of PCNSL by steroid treatment alone has been not infrequently reported [16] [17] [18] . Therefore, we postulated that intraarterial topical administration would produce even higher effects. Since no investigators have used such an approach, we investigated its feasibility in this study. That is, we used steroid infusion after standard treatment. We began with a single prednisolone dose of 30 mg, and finally reached the total dose of 100 mg. Fortunately, we have observed no acute or late complications so far. Thus, this approach appears to be quite feasible. There appeared to be no difference in feasibility between prednisolone and dexamethazone.
Once this approach proved to be feasible, tumor response to the treatment may be investigated in the next step. In this study, 6 of the 8 patients had achieved CR following radiotherapy, and tumor response to intraarterial corticosteroids could not be assessed in these patients. In the remaining two patients, the mass which persisted after radiation responded to the steroid treatment in one patient, but the persisting mass did not respond in the other patient and eventually showed regrowth. However, the mass persisting after radiotherapy may comprise of treatment-resistant subpopulations, so this case does not necessarily deny the antitumor effect of intraarterial steroid infusion. Although one of our patients had recurrent disease and 6 of the other 7 patients had multiple lesions, their median survival time was 26 months and their 2-year survival rate was 55%. These results compare favorably with those reported for 466 patients with PCNSL treated between 1985 and 1994 in our country (median survival: 18 months; 2-year survival: 40%) [2] . Prednisolone at the dose of 100 mg in total proved to be safe, and topical administration of such a high dose of steroid is expected to produce prominent reduction of PCNSL mass. In spite of the prominent effect of corticosteroids on PCNSL, their use in active treatment of PCNSL has been controversial [12, 17, 18] . One of the reasons is the adverse effect of steroids especially in long-term use. However, such a temporary use expected to produce high concentrations in tumor may be worthy of considering its incorporation into treatment regimens. The intraarterial steroid infusion can be used in combination with standard radiation and chemotherapy, and should be further evaluated in future studies. Based on these results, we have just started to use intraarterial steroid infusion before radiation therapy.
